Galectin-3 in Blood Serum and Lymphocytes as a Marker of Myocardial Damage in Patients with Arterial Hypertension and COVID-19

Hengel, F.E.; Sommer, C.; Wenzel, U. Arterielle Hypertonie - Eine Übersicht für den ärztlichen Alltag. Dtsch. Med. Wochenschr., 2022, 147(7), 414-428.
[http://dx.doi.org/10.1055/a-1577-8663] [PMID: 35345049]

Al Ghorani, H.; Götzinger, F.; Böhm, M.; Mahfoud, F. Arterial hypertension - Clinical trials update 2021. Nutr. Metab. Cardiovasc. Dis., 2022, 32(1), 21-31.
[http://dx.doi.org/10.1016/j.numecd.2021.09.007] [PMID: 34690044]

Mills, K.T.; Stefanescu, A.; He, J. The global epidemiology of hypertension. Nat. Rev. Nephrol., 2020, 16(4), 223-237.
[http://dx.doi.org/10.1038/s41581-019-0244-2] [PMID: 32024986]

Tackling, G.; Borhade, M.B. Hypertensive. Heart Dis. 2023.
[PMID: 30969622]

Kučera, T.; Jedličková, K.; Šramko, M.; Peichl, P.; Cvek, J.; Knybel, L.; Hurník, P.; Neuwirth, R.; Jiravský, O.; Voska, L.; Kautzner, J. Inflammation and fibrosis characterize different stages of myocardial remodeling in patients after stereotactic body radiotherapy of ventricular myocardium for recurrent ventricular tachycardia. Cardiovasc. Pathol., 2023, 62, 107488.
[http://dx.doi.org/10.1016/j.carpath.2022.107488] [PMID: 36206914]

Yao, Y.; Shen, D.; Chen, R.; Ying, C.; Wang, C.; Guo, J.; Zhang, G. Galectin-3 predicts left ventricular remodeling of hypertension. J. Clin. Hypertens. (Greenwich), 2016, 18(6), 506-511.
[http://dx.doi.org/10.1111/jch.12757] [PMID: 26693954]

Liu, M.; López de Juan Abad, B.; Cheng, K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies. Adv. Drug Deliv. Rev., 2021, 173, 504-519.
[http://dx.doi.org/10.1016/j.addr.2021.03.021] [PMID: 33831476]

Segura, A.M.; Frazier, O.H.; Buja, L.M. Fibrosis and heart failure. Heart Fail. Rev., 2014, 19(2), 173-185.
[http://dx.doi.org/10.1007/s10741-012-9365-4] [PMID: 23124941]

Weber, K.T.; Sun, Y.; Bhattacharya, S.K.; Ahokas, R.A.; Gerling, I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol., 2013, 10(1), 15-26.
[http://dx.doi.org/10.1038/nrcardio.2012.158] [PMID: 23207731]

Liu, H.; Liu, Y. Letter: Galectin-3: An important but insufficiently explored biomarker in cardiovascular disease. Angiology, 2023, 74(9), 897-898.
[http://dx.doi.org/10.1177/00033197231163699] [PMID: 36897306]

Bouffette, S.; Botez, I.; De Ceuninck, F. Targeting galectin-3 in inflammatory and fibrotic diseases. Trends Pharmacol. Sci., 2023, 44(8), 519-531.
[http://dx.doi.org/10.1016/j.tips.2023.06.001] [PMID: 37391294]

Yaluri, N. Stančáková Yaluri, A.; Žeňuch, P.; Žeňuchová, Z.; Tóth, Š.; Kalanin, P. Cardiac biomarkers and their role in identifying increased risk of cardiovascular complications in COVID-19 patients. Diagnostics (Basel), 2023, 13(15), 2508.
[http://dx.doi.org/10.3390/diagnostics13152508] [PMID: 37568870]

Wang, W.H.; Lin, C.Y.; Chang, M.R.; Urbina, A.N.; Assavalapsakul, W.; Thitithanyanont, A.; Chen, Y.H.; Liu, F.T.; Wang, S.F. The role of galectins in virus infection - A systemic literature review. J. Microbiol. Immunol. Infect., 2020, 53(6), 925-935.
[http://dx.doi.org/10.1016/j.jmii.2019.09.005] [PMID: 31630962]

Dong, R.; Zhang, M.; Hu, Q.; Zheng, S.; Soh, A.; Zheng, Y.; Yuan, H. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int. J. Mol. Med. , 2018, 41(2), 599-614. [Review].
[PMID: 29207027]

Blanda, V.; Bracale, U.M.; Di Taranto, M.D.; Fortunato, G. Galectin-3 in cardiovascular diseases. Int. J. Mol. Sci., 2020, 21(23), 9232.
[http://dx.doi.org/10.3390/ijms21239232] [PMID: 33287402]

Suthahar, N.; Meijers, W.C.; Silljé, H.H.W.; Ho, J.E.; Liu, F.T.; de Boer, R.A. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: An update. Theranostics, 2018, 8(3), 593-609.
[http://dx.doi.org/10.7150/thno.22196] [PMID: 29344292]

Zaborska, B.; Sikora-Frąc, M.; Smarż, K.; Pilichowska-Paszkiet, E.; Budaj, A.; Sitkiewicz, D.; Sygitowicz, G. The role of galectin-3 in heart failure—the diagnostic, prognostic and therapeutic potential—where do we stand? Int. J. Mol. Sci., 2023, 24(17), 13111.
[http://dx.doi.org/10.3390/ijms241713111] [PMID: 37685918]

Screever, E.M.; Gorter, T.M.; Willems, T.P.; Aboumsallem, J.P.; Suthahar, N.; Mahmoud, B.; van Veldhuisen, D.J.; de Boer, R.A.; Meijers, W.C. Diffuse myocardial fibrosis on cardiac magnetic resonance imaging is related to galectin-3 and predicts outcome in heart failure. Biomolecules, 2023, 13(3), 410.
[http://dx.doi.org/10.3390/biom13030410] [PMID: 36979345]

de Boer, R.A.; van der Velde, A.R.; Mueller, C.; van Veldhuisen, D.J.; Anker, S.D.; Peacock, W.F.; Adams, K.F.; Maisel, A. Galectin-3: a modifiable risk factor in heart failure. Cardiovasc. Drugs Ther., 2014, 28(3), 237-246.
[http://dx.doi.org/10.1007/s10557-014-6520-2] [PMID: 24789662]

López, B.; González, A.; Querejeta, R.; Zubillaga, E.; Larman, M.; Díez, J. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin. Eur. J. Heart Fail., 2015, 17(4), 385-392.
[http://dx.doi.org/10.1002/ejhf.246] [PMID: 25684565]

Portacci, A.; Diaferia, F.; Santomasi, C.; Dragonieri, S.; Boniello, E.; Di Serio, F.; Carpagnano, G.E. Galectin-3 as prognostic biomarker in patients with COVID-19 acute respiratory failure. Respir. Med., 2021, 187, 106556.
[http://dx.doi.org/10.1016/j.rmed.2021.106556] [PMID: 34375925]

Turnic, T.N.; Popadic, V.; Klasnja, S.; Sekulic, A.; Nikolic, N.; Zivkovic, V.; Jeremic, N.; Andjic, M.; Draginic, N.; Srejovic, I.; Jeremic, J.; Zdravkovic, M.; Jakovljevic, V. Bradykinin and galectin-3 in survived and deceased patients with COVID-19 pneumonia: An increasingly promising biochemical target. Oxid. Med. Cell. Longev., 2022, 2022, 1-14.
[http://dx.doi.org/10.1155/2022/7920915] [PMID: 36338343]

Sygitowicz, G. Maciejak-Jastrzębska, A.; Sitkiewicz, D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules, 2021, 12(1), 46.
[http://dx.doi.org/10.3390/biom12010046] [PMID: 35053194]

Liu, H.; Hwang, S.Y.; Lee, S.S. Role of galectin in cardiovascular conditions including cirrhotic cardiomyopathy. Pharmaceuticals (Basel), 2023, 16(7), 978.
[http://dx.doi.org/10.3390/ph16070978] [PMID: 37513890]

Kazancioglu, S.; Yilmaz, F.M.; Bastug, A.; Ozbay, B.O.; Aydos, O.; Yücel, Ç.; Bodur, H.; Yilmaz, G. Assessment of galectin-1, galectin-3, and prostaglandin e2 levels in patients with COVID-19. Jpn. J. Infect. Dis., 2021, 74(6), 530-536.
[http://dx.doi.org/10.7883/yoken.JJID.2021.020] [PMID: 33790073]

de Boer, R.A.; Edelmann, F.; Cohen-Solal, A.; Mamas, M.A.; Maisel, A.; Pieske, B. Galectin‐3 in heart failure with preserved ejection fraction. Eur. J. Heart Fail., 2013, 15(10), 1095-1101.
[http://dx.doi.org/10.1093/eurjhf/hft077] [PMID: 23650131]

Florido, R.; Kwak, L.; Echouffo-Tcheugui, J.B.; Zhang, S.; Michos, E.D.; Nambi, V.; Goldberg, R.B.; Hoogeveen, R.C.; Lazo, M.; Gerstenblith, G.; Post, W.S.; Blumenthal, R.S.; Coresh, J.; Folsom, A.R.; Selvin, E.; Ballantyne, C.; Ndumele, C.E. Obesity, Galectin‐3, and Incident Heart Failure: The ARIC Study. J. Am. Heart Assoc., 2022, 11(9), e023238.
[http://dx.doi.org/10.1161/JAHA.121.023238] [PMID: 35491999]

Zhang, Z.; Wang, Y. Management of cardiovascular diseases in chronic hemodialysis patients. Rev. Cardiovasc. Med., 2023, 24(7), 185.
[http://dx.doi.org/10.31083/j.rcm2407185]

van Kimmenade, R.R.; Januzzi, J.L., Jr; Ellinor, P.T.; Sharma, U.C.; Bakker, J.A.; Low, A.F.; Martinez, A.; Crijns, H.J.; MacRae, C.A.; Menheere, P.P.; Pinto, Y.M. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol., 2006, 48(6), 1217-1224.
[http://dx.doi.org/10.1016/j.jacc.2006.03.061] [PMID: 16979009]

Aleksova, A.; Sinagra, G.; Beltrami, A.P.; Pierri, A.; Ferro, F.; Janjusevic, M.; Gagno, G. Biomarkers in the management of acute heart failure: state of the art and role in COVID‐19 era. ESC Heart Fail., 2021, 8(6), 4465-4483.
[http://dx.doi.org/10.1002/ehf2.13595] [PMID: 34609075]

Hogas, S.; Bilha, S.C.; Branisteanu, D.; Hogas, M.; Gaipov, A.; Kanbay, M.; Covic, A. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Arch. Med. Sci., 2017, 4(4), 897-913.
[http://dx.doi.org/10.5114/aoms.2016.58664] [PMID: 28721158]

Stojanovic, B.S.; Stojanovic, B.; Milovanovic, J.; Arsenijević, A.; Dimitrijevic Stojanovic, M.; Arsenijevic, N.; Milovanovic, M. The pivotal role of galectin-3 in viral infection: a multifaceted player in host-pathogen interactions. Int. J. Mol. Sci., 2023, 24(11), 9617.
[http://dx.doi.org/10.3390/ijms24119617] [PMID: 37298569]

Garcia-Revilla, J.; Deierborg, T.; Venero, J.L.; Boza-Serrano, A. Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider. Front. Immunol., 2020, 11, 2069.
[http://dx.doi.org/10.3389/fimmu.2020.02069] [PMID: 32973815]

Grewal, T.; Buechler, C. Adipokines as diagnostic and prognostic markers for the severity of COVID-19. Biomedicines, 2023, 11(5), 1302.
[http://dx.doi.org/10.3390/biomedicines11051302] [PMID: 37238973]

Kuśnierz-Cabala, B.; Maziarz, B.; Dumnicka, P.; Dembiński, M.; Kapusta, M.; Bociąga-Jasik, M.; Winiarski, M.; Garlicki, A.; Grodzicki, T.; Kukla, M. Diagnostic significance of serum galectin-3 in hospitalized patients with COVID-19—A preliminary study. Biomolecules, 2021, 11(8), 1136.
[http://dx.doi.org/10.3390/biom11081136] [PMID: 34439802]

Tawiah, K.; Jackson, L.; Omosule, C.; Ballman, C.; Shahideh, B.; Scott, M.G.; Murtagh, G.; Farnsworth, C.W. Serial cardiac biomarkers for risk stratification of patients with COVID-19. Clin. Biochem., 2022, 107, 24-32.
[http://dx.doi.org/10.1016/j.clinbiochem.2022.06.002] [PMID: 35691587]

Cervantes-Alvarez, E.; la Rosa, N.L. Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci. Reports., 2022, 12, 1-9.

Kartal Baykan, E. ; ŞEBİN, E.E.; Karaşahı̇n, Ö.; Baykan, A.R. Galectin- 3: can it be a diagnostic tool for pneumonia in covid-19 patients? TURKISH J. Med. Sci., , 2021, 51, 2256-2262.

Liu, F.T.; Stowell, S.R. The role of galectins in immunity and infection. Nat. Rev. Immunol., 2023, 23(8), 479-494.
[http://dx.doi.org/10.1038/s41577-022-00829-7] [PMID: 36646848]

Reddy, K.; Nichol, A.; McAuley, D.F. Galectin-3 Inhibition in COVID-19. Am. J. Respir. Crit. Care Med., 2023, 207(2), 118-120.
[http://dx.doi.org/10.1164/rccm.202209-1758ED] [PMID: 36154818]

Mendes-Frias, A.; Gallo, V.; Iacobelli, V.; Gentile, R.; Antonini, G.; Silvestre, R.; Iacobelli, S. Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines. Sci. Rep., 2022, 12(1), 17047.
[http://dx.doi.org/10.1038/s41598-022-20852-x] [PMID: 36220879]

Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.L.; Coca, A.; de Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.E.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.E.; Shlyakhto, E.; Tsioufis, C.; Aboyans, V.; Desormais, I.; De Backer, G.; Heagerty, A.M.; Agewall, S.; Bochud, M.; Borghi, C.; Boutouyrie, P.; Brguljan, J.; Bueno, H.; Caiani, E.G.; Carlberg, B.; Chapman, N.; Cífková, R.; Cleland, J.G.F.; Collet, J-P.; Coman, I.M.; de Leeuw, P.W.; Delgado, V.; Dendale, P.; Diener, H-C.; Dorobantu, M.; Fagard, R.; Farsang, C.; Ferrini, M.; Graham, I.M.; Grassi, G.; Haller, H.; Hobbs, F.D.R.; Jelakovic, B.; Jennings, C.; Katus, H.A.; Kroon, A.A.; Leclercq, C.; Lovic, D.; Lurbe, E.; Manolis, A.J.; McDonagh, T.A.; Messerli, F.; Muiesan, M.L.; Nixdorff, U.; Olsen, M.H.; Parati, G.; Perk, J.; Piepoli, M.F.; Polonia, J.; Ponikowski, P.; Richter, D.J.; Rimoldi, S.F.; Roffi, M.; Sattar, N.; Seferovic, P.M.; Simpson, I.A.; Sousa-Uva, M.; Stanton, A.V.; van de Borne, P.; Vardas, P.; Volpe, M.; Wassmann, S.; Windecker, S.; Zamorano, J.L.; Windecker, S.; Aboyans, V.; Agewall, S.; Barbato, E.; Bueno, H.; Coca, A.; Collet, J-P.; Coman, I.M.; Dean, V.; Delgado, V.; Fitzsimons, D.; Gaemperli, O.; Hindricks, G.; Iung, B.; Jüni, P.; Katus, H.A.; Knuuti, J.; Lancellotti, P.; Leclercq, C.; McDonagh, T.A.; Piepoli, M.F.; Ponikowski, P.; Richter, D.J.; Roffi, M.; Shlyakhto, E.; Simpson, I.A.; Sousa-Uva, M.; Zamorano, J.L.; Tsioufis, C.; Lurbe, E.; Kreutz, R.; Bochud, M.; Rosei, E.A.; Jelakovic, B.; Azizi, M.; Januszewics, A.; Kahan, T.; Polonia, J.; van de Borne, P.; Williams, B.; Borghi, C.; Mancia, G.; Parati, G.; Clement, D.L.; Coca, A.; Manolis, A.; Lovic, D.; Benkhedda, S.; Zelveian, P.; Siostrzonek, P.; Najafov, R.; Pavlova, O.; De Pauw, M.; Dizdarevic-Hudic, L.; Raev, D.; Karpettas, N.; Linhart, A.; Olsen, M.H.; Shaker, A.F.; Viigimaa, M.; Metsärinne, K.; Vavlukis, M.; Halimi, J-M.; Pagava, Z.; Schunkert, H.; Thomopoulos, C.; Páll, D.; Andersen, K.; Shechter, M.; Mercuro, G.; Bajraktari, G.; Romanova, T.; Trušinskis, K.; Saade, G.A.; Sakalyte, G.; Noppe, S.; DeMarco, D.C.; Caraus, A.; Wittekoek, J.; Aksnes, T.A.; Jankowski, P.; Polonia, J.; Vinereanu, D.; Baranova, E.I.; Foscoli, M.; Dikic, A.D.; Filipova, S.; Fras, Z.; Bertomeu-Martínez, V.; Carlberg, B.; Burkard, T.; Sdiri, W.; Aydogdu, S.; Sirenko, Y.; Brady, A.; Weber, T.; Lazareva, I.; Backer, T.D.; Sokolovic, S.; Jelakovic, B.; Widimsky, J.; Viigimaa, M.; Pörsti, I.; Denolle, T.; Krämer, B.K.; Stergiou, G.S.; Parati, G.; Trušinskis, K.; Miglinas, M.; Gerdts, E.; Tykarski, A.; de Carvalho Rodrigues, M.; Dorobantu, M.; Chazova, I.; Lovic, D.; Filipova, S.; Brguljan, J.; Segura, J.; Gottsäter, A.; Pechère-Bertschi, A.; Erdine, S.; Sirenko, Y.; Brady, A. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J., 2018, 39(33), 3021-3104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]

Hara, A.; Niwa, M.; Noguchi, K.; Kanayama, T.; Niwa, A.; Matsuo, M.; Hatano, Y.; Tomita, H. Galectin-3 as a next-generation biomarker for detecting early stage of various diseases. Biomolecules, 2020, 10(3), 389.
[http://dx.doi.org/10.3390/biom10030389] [PMID: 32138174]

Castiglione, V.; Aimo, A.; Vergaro, G.; Saccaro, L.; Passino, C.; Emdin, M. Biomarkers for the diagnosis and management of heart failure. Heart Fail. Rev., 2022, 27(2), 625-643.
[http://dx.doi.org/10.1007/s10741-021-10105-w] [PMID: 33852110]

Baccouche, B.M.; Mahmoud, M.A.; Nief, C.; Patel, K.; Natterson-Horowitz, B. Galectin-3 is associated with heart failure incidence: A meta-analysis. Curr. Cardiol. Rev., 2023, 19(3), e171122211004.
[http://dx.doi.org/10.2174/1573403X19666221117122012] [PMID: 36397629]

Rabkin, S.W.; Tang, J.K.K. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review. Heart Fail. Rev., 2021, 26(4), 799-812.
[http://dx.doi.org/10.1007/s10741-020-09913-3] [PMID: 32472523]

Soares, L.C.; Al-Dalahmah, O.; Hillis, J.; Young, C.C.; Asbed, I.; Sakaguchi, M.; O’Neill, E.; Szele, F.G. Novel galectin-3 roles in neurogenesis, inflammation and neurological diseases. Cells, 2021, 10(11), 3047.
[http://dx.doi.org/10.3390/cells10113047] [PMID: 34831271]

Martínez-Martínez, E.; Brugnolaro, C.; Ibarrola, J.; Ravassa, S.; Buonafine, M.; López, B.; Fernández-Celis, A.; Querejeta, R.; Santamaria, E.; Fernández-Irigoyen, J.; Rábago, G.; Moreno, M.U.; Jaisser, F.; Díez, J.; González, A.; López-Andrés, N. CT-1 (cardiotrophin-1)-gal-3 (galectin-3) axis in cardiac fibrosis and inflammation. Hypertension, 2019, 73(3), 602-611.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.11874] [PMID: 30612490]

Hu, G.; Wu, J.; Gu, H.; Deng, X.; Xu, W.; Feng, S.; Wang, S.; Song, Y.; Pang, Z.; Deng, X.; Vendrov, A.E.; Madamanchi, N.R.; Runge, M.S.; Wang, X.; Zhang, Y.; Xiao, H.; Dong, E. Galectin-3-centered paracrine network mediates cardiac inflammation and fibrosis upon β-adrenergic insult. Sci. China Life Sci., 2023, 66(5), 1067-1078.
[http://dx.doi.org/10.1007/s11427-022-2189-x] [PMID: 36449214]

Gao, Z.; Liu, Z.; Wang, R.; Zheng, Y.; Li, H.; Yang, L. Galectin-3 is a potential mediator for atherosclerosis. J. Immunol. Res., 2020, 2020, 1-11.
[http://dx.doi.org/10.1155/2020/5284728] [PMID: 32149158]

Puccini, M.; Jakobs, K.; Reinshagen, L.; Friebel, J.; Schencke, P.A.; Ghanbari, E.; Landmesser, U.; Haghikia, A.; Kränkel, N.; Rauch, U. Galectin-3 as a marker for increased thrombogenicity in COVID-19. Int. J. Mol. Sci., 2023, 24(9), 7683.
[http://dx.doi.org/10.3390/ijms24097683] [PMID: 37175392]

Özcan, S.; Dönmez, E.; Yavuz, S.T; Ziyrek, M.; İnce, O.; Küçük, H.S; Taşdemir, Z.A; Yılmaz, İ.; Varol, S.; Şahin, İ.; Okuyan, E. Prognostic significance of serum galectin-3 in hospitalized patients with COVID-19. Cytokine, 2022, 158, 155970.
[http://dx.doi.org/10.1016/j.cyto.2022.155970] [PMID: 35917725]

Agnello, L.; Bivona, G.; Lo Sasso, B.; Scazzone, C.; Bazan, V.; Bellia, C.; Ciaccio, M. Galectin-3 in acute coronary syndrome. Clin. Biochem., 2017, 50(13-14), 797-803.
[http://dx.doi.org/10.1016/j.clinbiochem.2017.04.018] [PMID: 28456545]

Slack, R.J.; Mills, R.; Mackinnon, A.C. The therapeutic potential of galectin-3 inhibition in fibrotic disease. Int. J. Biochem. Cell Biol., 2021, 130, 105881.
[http://dx.doi.org/10.1016/j.biocel.2020.105881] [PMID: 33181315]

Karsli, E.; Anabarli Metin, D.; Canacik, O.; Sabirli, R.; Kaymaz, B.; Kurt, O.; Koseler, A. Galectin-3 as a potential prognostic biomarker for COVID-19 disease: A case-control study. Cureus, 2022, 14(9), e28805.
[http://dx.doi.org/10.7759/cureus.28805] [PMID: 36225452]

Gajovic, N.; Sekulic Markovic, S.; Jurisevic, M.; Jovanovic, M. Galectin-3 as an important prognostic marker for COVID-19 severity. Sci. Reports., 2023, 13(1), 1460.

Sindrewicz, P.; Yates, E.A.; Turnbull, J.E.; Lian, L.Y.; Yu, L.G. Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure. Biochem. Biophys. Res. Commun., 2020, 523(2), 336-341.
[http://dx.doi.org/10.1016/j.bbrc.2019.12.054] [PMID: 31866013]

Duckworth, C.A.; Guimond, S.E.; Sindrewicz, P.; Hughes, A.J.; French, N.S.; Lian, L.Y.; Yates, E.A.; Pritchard, D.M.; Rhodes, J.M.; Turnbull, J.E.; Yu, L.G. Chemically modified, non-anticoagulant heparin derivatives are potent galectin-3 binding inhibitors and inhibit circulating galectin-3-promoted metastasis. Oncotarget, 2015, 6(27), 23671-23687.
[http://dx.doi.org/10.18632/oncotarget.4409] [PMID: 26160844]

Jia, X.; Sun, C.; Tanaka, H.; Al Rifai, M.; Aguilar, D.; Ndumele, C.; Selvin, E.; Virani, S.S.; Hoogeveen, R.C.; Heiss, G.; Ballantyne, C.M.; Nambi, V. Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa, 2021, 50(6), 439-445.
[http://dx.doi.org/10.1024/0301-1526/a000968] [PMID: 34346252]

Sherpa, M.D.; Sonkawade, S.D.; Jonnala, V.; Pokharel, S.; Khazaeli, M.; Yatsynovich, Y.; Kalot, M.A.; Weil, B.R.; Canty, J.M., Jr; Sharma, U.C. Galectin-3 is associated with cardiac fibrosis and an increased risk of sudden death. Cells, 2023, 12(9), 1218.
[http://dx.doi.org/10.3390/cells12091218] [PMID: 37174619]

Meijers, W.C.; López-Andrés, N.; de Boer, R.A. Galectin-3, cardiac function, and fibrosis. Am. J. Pathol., 2016, 186(8), 2232-2234.
[http://dx.doi.org/10.1016/j.ajpath.2016.05.002] [PMID: 27461364]

Gehlken, C.; Suthahar, N.; Meijers, W.C.; de Boer, R.A. Galectin-3 in heart failure. Heart Fail. Clin., 2018, 14(1), 75-92.
[http://dx.doi.org/10.1016/j.hfc.2017.08.009] [PMID: 29153203]

Humphrey, J.D. Mechanisms of vascular remodeling in hypertension. Am. J. Hypertens., 2021, 34(5), 432-441.
[http://dx.doi.org/10.1093/ajh/hpaa195] [PMID: 33245319]

Díez, J. Arterial hypertension in patients with heart failure. Heart Fail. Clin., 2014, 10(2), 233-242.
[http://dx.doi.org/10.1016/j.hfc.2013.12.004] [PMID: 24656102]

Bošnjak, I.; Bedeković, D.; Selthofer-Relatić, K.; Roguljić, H.; Mihaljević, I.; Bilić-Ćurčić, I. Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease. BMC Cardiovasc. Disord., 2023, 23(1), 268.
[http://dx.doi.org/10.1186/s12872-023-03310-y] [PMID: 37221462]

Anyfanti, P.; Gkaliagkousi, E.; Gavriilaki, E.; Triantafyllou, A.; Dolgyras, P.; Galanopoulou, V.; Aslanidis, S.; Douma, S. Association of galectin‐3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis. Clin. Cardiol., 2019, 42(1), 62-68.
[http://dx.doi.org/10.1002/clc.23105] [PMID: 30353563]

Hara, A.; Niwa, M.; Kanayama, T.; Noguchi, K.; Niwa, A.; Matsuo, M.; Kuroda, T.; Hatano, Y.; Okada, H.; Tomita, H. Galectin-3: A potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules, 2020, 10(9), 1277.
[http://dx.doi.org/10.3390/biom10091277] [PMID: 32899694]

Acharya, S.; Kumar, S.; Talwar, D.; Raisinghani, N.; Madaan, S.; Hulkoti, V.; Akhilesh, A.; Khanna, S.; Shah, D.; Nimkar, S. Interleukin 6 and its correlation with COVID-19 in terms of outcomes in an intensive care unit of a rural hospital: a cross-sectional study. Indian J. Crit. Care Med., 2022, 26(1), 39-42.
[http://dx.doi.org/10.5005/jp-journals-10071-24075] [PMID: 35110842]

Yudhawati, R.; Sakina, S.; Fitriah, M. Interleukin-1β and interleukin-10 profiles and ratio in serum of COVID-19 patients and correlation with COVID-19 severity: A time series study. Int. J. Gen. Med., 2022, 15, 8043-8054.
[http://dx.doi.org/10.2147/IJGM.S381404] [PMID: 36389025]

Baykiz, D.; Emet, S.; Ayduk-Govdeli, E.; Kaytaz, M.; Yavuz, M.; Karaca-Ozer, P.; Karaayvaz, E.; Medetalibeyoglu, A.; Elitok, A.; Genc, S.; Bugra, Z.; Umman, B. Galectin-3 as a novel biomarker for predicting clinical outcomes in hospitalized COVID-19 Patients. Clin. Lab., , 2022, 68(12/2022), 2483-2495.
[http://dx.doi.org/10.7754/Clin.Lab.2022.220134] [PMID: 36546745]

Berber, N.K.; Geçkil, A.A.; Altan, N.Ö.; Kıran, T.R; Otlu, Ö.; Erdem, M.; İn, E. Efficacy of serum apelin and galectin‐3 as potential predictors of mortality in severe COVID‐19 patients. J. Med. Virol., 2023, 95(2), e28494.
[http://dx.doi.org/10.1002/jmv.28494] [PMID: 36633201]

Gaughan, E.E.; Quinn, T.M.; Mills, A.; Bruce, A.M.; Antonelli, J.; MacKinnon, A.C.; Aslanis, V.; Li, F.; O’Connor, R.; Boz, C.; Mills, R.; Emanuel, P.; Burgess, M.; Rinaldi, G.; Valanciute, A.; Mills, B.; Scholefield, E.; Hardisty, G.; Findlay, E.G.; Parker, R.A.; Norrie, J.; Dear, J.W.; Akram, A.R.; Koch, O.; Templeton, K.; Dockrell, D.H.; Walsh, T.S.; Partridge, S.; Humphries, D.; Wang-Jairaj, J.; Slack, R.J.; Schambye, H.; Phung, D.; Gravelle, L.; Lindmark, B.; Shankar-Hari, M.; Hirani, N.; Sethi, T.; Dhaliwal, K. An inhaled galectin-3 inhibitor in COVID-19 pneumonitis: A phase Ib/IIa randomized controlled clinical trial (DEFINE). Am. J. Respir. Crit. Care Med., 2023, 207(2), 138-149.
[http://dx.doi.org/10.1164/rccm.202203-0477OC] [PMID: 35972987]

Bruni, F.; Charitos, P.; Lampart, M.; Moser, S.; Siegemund, M.; Bingisser, R.; Osswald, S.; Bassetti, S.; Twerenbold, R.; Trendelenburg, M.; Rentsch, K.M.; Osthoff, M. Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study. Front. Immunol., 2022, 13, 941742.
[http://dx.doi.org/10.3389/fimmu.2022.941742] [PMID: 36203596]